Association of microRNAs and pathologic response to preoperative chemotherapy in triple negative breast cancer: preliminary report

Triple negative breast cancer (TNBC) has caught the attention of oncologists worldwide because of poor prognosis and paucity of targeted therapies. Gene pathways have been widely studied, but less is known about epigenetic factors such as microRNAs (miRNAs) and their role in tailoring an individual systemic and surgical approach for breast cancer patients. The aim of the study was to examine selected miRNAs in TNBC core biopsies sampled before preoperative chemotherapy and the subsequent pathologic response in mastectomy or breast conservation specimens. Prior to treatment, core needle biopsies were collected from 11 female patients with inoperable locally advanced TNBC or large resectable tumors suitable for down-staging. In all 11 TNBC core biopsies we analyzed 19 miRNAs per sample: 512, 190, 200, 346, 148, 449, 203, 577, 93, 126, 423, 129, 193, 182, 136, 135, 191, 122 and 222 (miRCURY LNA™ Universal RT microRNA polymerase chain reaction Custom Pick & Mixpanels). The Wilcoxon signed-rank test was used to compare related samples. Ingenuity pathway analysis was used to evaluate potential functional significance of differentially expressed miRNAs. Statistical analysis showed that 3 of 19 miRNAs differed in relation to pathologic response i.e. good versus poor. These differences failed to reach statistical significance, although a trend was observed (p = 0.06). Among these miRNAs, we identified—miR-200b-3p, miR-190a and miR-512-5p. In summary, our results indicate that higher miR-200b-3p, higher miR-190a and lower miR-512-5p expression levels in core biopsies sampled from TNBC patients may be associated with better pathologic response to chemotherapy and the increased feasibility of breast conserving surgery in these patients. Although these results were from a small cohort, they provide an important basis for larger, prospective, multicenter studies to investigate the potential role of miRNAs in neoadjuvant setting.

[1]  Christos Hatzis,et al.  Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  C. Bokemeyer,et al.  Micro-RNA expression in cisplatin resistant germ cell tumor cell lines , 2011, Molecular Cancer.

[3]  Andrey Golubov,et al.  Alterations of microRNAs and their targets are associated with acquired resistance of MCF‐7 breast cancer cells to cisplatin , 2010, International journal of cancer.

[4]  I. Pogribny,et al.  E‐cadherin transcriptional down‐regulation by epigenetic and microRNA‐200 family alterations is related to mesenchymal and drug‐resistant phenotypes in human breast cancer cells , 2010, International journal of cancer.

[5]  R. Bast,et al.  Plasma microRNA 210 levels correlate with sensitivity to trastuzumab and tumor presence in breast cancer patients , 2012, Cancer.

[6]  G. von Minckwitz,et al.  Neoadjuvant treatments for triple-negative breast cancer (TNBC). , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[7]  J. Li,et al.  MiR-200b and miR-15b regulate chemotherapy-induced epithelial-mesenchymal transition in human tongue cancer cells by targeting BMI1 , 2012, Oncogene.

[8]  P. Fasching,et al.  Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  L. Hlatky,et al.  Consensus Micro RNAs Governing the Switch of Dormant Tumors to the Fast-Growing Angiogenic Phenotype , 2012, PloS one.

[10]  Burton B. Yang,et al.  The non-coding 3′ UTR of CD44 induces metastasis by regulating extracellular matrix functions , 2012, Journal of Cell Science.

[11]  M. Piccart.  Triple-negative breast cancer in focus: from biology to novel therapeutics. Editorial. , 2012, Annals of Oncology.

[12]  Burton B. Yang,et al.  The non-coding 3′ UTR of CD44 induces metastasis by regulating extracellular matrix functions , 2012, Journal of Cell Science.

[13]  L. Hlatky,et al.  Transcriptional changes induced by the tumor dormancy-associated microRNA-190 , 2013, Transcription.

[14]  S. Loibl,et al.  Update on neoadjuvant/preoperative therapy of breast cancer: experiences from the German Breast Group , 2013, Current opinion in obstetrics & gynecology.

[15]  Andrea Sottoriva,et al.  The shaping and functional consequences of the microRNA landscape in breast cancer , 2013, Nature.

[16]  P. Tan,et al.  Identification of Circulating MicroRNA Signatures for Breast Cancer Detection , 2013, Clinical Cancer Research.

[17]  P. Fasching,et al.  Ki67 Measured after Neoadjuvant Chemotherapy for Primary Breast Cancer , 2013, Clinical Cancer Research.

[18]  C. Perou,et al.  The genomic landscape of breast cancer as a therapeutic roadmap. , 2013, Cancer discovery.

[19]  R. Datar,et al.  Genetic and epigenetic analysis of putative breast cancer stem cell models , 2013, BMC Cancer.